Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Alzheimer Disease : Standard of Diagnosis, Treatment, Care, and Prevention

Teipel, Stefan ; Gustafson, Deborah ; Ossenkoppele, Rik LU ; Hansson, Oskar LU orcid ; Babiloni, Claudio ; Wagner, Michael ; Riedel-Heller, Steffi G. ; Kilimann, Ingo and Tang, Yi (2022) In Journal of Nuclear Medicine 63(7). p.981-985
Abstract

Alzheimer disease (AD) is the most frequent cause of dementia in people 60 y old or older. This white paper summarizes the current standards of AD diagnosis, treatment, care, and prevention. Cerebrospinal fluid and PET measures of cerebral amyloidosis and tauopathy allow the diagnosis of AD even before dementia (prodromal stage) and provide endpoints for treatments aimed at slowing the AD course. Licensed pharmacologic symptomatic drugs enhance cholinergic pathways and moderate excess of glutamatergic transmission to stabilize cognition. Disease-modifying experimental drugs moderate or remove brain amyloidosis, but so far with modest clinical effects. Nonpharmacologic interventions and a healthy lifestyle (diet, socioaffective... (More)

Alzheimer disease (AD) is the most frequent cause of dementia in people 60 y old or older. This white paper summarizes the current standards of AD diagnosis, treatment, care, and prevention. Cerebrospinal fluid and PET measures of cerebral amyloidosis and tauopathy allow the diagnosis of AD even before dementia (prodromal stage) and provide endpoints for treatments aimed at slowing the AD course. Licensed pharmacologic symptomatic drugs enhance cholinergic pathways and moderate excess of glutamatergic transmission to stabilize cognition. Disease-modifying experimental drugs moderate or remove brain amyloidosis, but so far with modest clinical effects. Nonpharmacologic interventions and a healthy lifestyle (diet, socioaffective inclusion, cognitive stimulation, physical exercise, and others) provide some beneficial effects. Prevention targets mainly modifiable dementia risk factors such as unhealthy lifestyle, cardiovascular–metabolic and sleep–wake cycle abnormalities, and mental disorders. A major challenge for the future is telemonitoring in the real world of these modifiable risk factors.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
amyloid, biomarkers, dementia, PET, prevention, treatment
in
Journal of Nuclear Medicine
volume
63
issue
7
pages
5 pages
publisher
Society of Nuclear Medicine
external identifiers
  • scopus:85133861291
  • pmid:35145015
ISSN
0161-5505
DOI
10.2967/jnumed.121.262239
language
English
LU publication?
yes
id
c405f5f5-feea-46d7-a3a3-86b1cfdd4a11
date added to LUP
2022-09-26 15:16:30
date last changed
2024-06-14 17:43:45
@article{c405f5f5-feea-46d7-a3a3-86b1cfdd4a11,
  abstract     = {{<p>Alzheimer disease (AD) is the most frequent cause of dementia in people 60 y old or older. This white paper summarizes the current standards of AD diagnosis, treatment, care, and prevention. Cerebrospinal fluid and PET measures of cerebral amyloidosis and tauopathy allow the diagnosis of AD even before dementia (prodromal stage) and provide endpoints for treatments aimed at slowing the AD course. Licensed pharmacologic symptomatic drugs enhance cholinergic pathways and moderate excess of glutamatergic transmission to stabilize cognition. Disease-modifying experimental drugs moderate or remove brain amyloidosis, but so far with modest clinical effects. Nonpharmacologic interventions and a healthy lifestyle (diet, socioaffective inclusion, cognitive stimulation, physical exercise, and others) provide some beneficial effects. Prevention targets mainly modifiable dementia risk factors such as unhealthy lifestyle, cardiovascular–metabolic and sleep–wake cycle abnormalities, and mental disorders. A major challenge for the future is telemonitoring in the real world of these modifiable risk factors.</p>}},
  author       = {{Teipel, Stefan and Gustafson, Deborah and Ossenkoppele, Rik and Hansson, Oskar and Babiloni, Claudio and Wagner, Michael and Riedel-Heller, Steffi G. and Kilimann, Ingo and Tang, Yi}},
  issn         = {{0161-5505}},
  keywords     = {{amyloid; biomarkers; dementia; PET; prevention; treatment}},
  language     = {{eng}},
  month        = {{07}},
  number       = {{7}},
  pages        = {{981--985}},
  publisher    = {{Society of Nuclear Medicine}},
  series       = {{Journal of Nuclear Medicine}},
  title        = {{Alzheimer Disease : Standard of Diagnosis, Treatment, Care, and Prevention}},
  url          = {{http://dx.doi.org/10.2967/jnumed.121.262239}},
  doi          = {{10.2967/jnumed.121.262239}},
  volume       = {{63}},
  year         = {{2022}},
}